4′-fluoro nucleosides for the treatment of HCV

US9211300B2 · kind B2 · utility

Assignees

• Idenix Pharmaceuticals LLC · US
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES · FR

Inventors

• Benjamin Alexander Mayes · Boston, US
• Adel Moussa · Burlington, US
• Alistair James Stewart · Lincoln, US
• Gilles Gosselin · Montpellier, FR

Key dates

• Filing date: Dec 17, 2013
• Grant date: Dec 15, 2015
• Expiry date: Dec 17, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/213
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501:or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.